A review published today in JAMA Otolaryngology–Head & Neck Surgery does the sorting that sleep-apnea patients have needed since tirzepatide was approved for the condition in December 2024. Obstructive sleep apnea affects close to a billion adults worldwide, obesity is present in 60–70% of cases, and the standard treatment, a CPAP machine, works but is used consistently by only 30–60% of the people prescribed it. Across six meta-analyses, GLP-1 drugs cut the number of breathing interruptions per hour by roughly six to twenty-two; in the pivotal tirzepatide trial, by 20–24, with 42–50% of patients reaching remission. CPAP, used, cuts about 31. The authors' conclusion is the sensible one: the drugs are a complement to the machine, best suited to patients with obesity who cannot tolerate it, not a replacement.
Why this is a sleep post, not a drug post. Untreated apnea is one of the most common and most damaging sleep problems we see, and it is underdiagnosed in exactly the people who buy sleep gadgets: snorers who wake tired and are told by a ring that their sleep score is 71. The news here is that medicine now has two real tools for it and an honest comparison between them. The machine wins on effect; the drug wins on adherence for some; the review notes that the drug's heart benefits in this population are unproven and that weight, and apnea, return when it stops. None of that is available from tape, a pillow or an app.
Loree’s takeIf you snore, wake unrefreshed or have been told you stop breathing at night, the first step is still a sleep study, not a prescription and not a device. Once there is a diagnosis, this review is the conversation: CPAP if you will wear it, a GLP-1 if you have obesity and cannot, sometimes both. What I will not accept is the version of this story that turns a drug for a diagnosed condition into a sleep hack for people who have never been tested.
Ben’s takeThe market will read this review as a growth story for GLP-1s, and it is one. The number I would underline is the other one — 30 to 60% adherence to a treatment that works better. The highest-value intervention in sleep apnea is getting people to use the thing that already exists, and nobody makes money on that. It is the same gap as in the fundamentals: the effective option is cheap and unglamorous, and the glamorous option gets the marketing.
Snoring and waking tired? Get a sleep study before any product. Then use the treatment that works, even if it hums.
This post reports on evidence and expert disagreement. It is not medical advice; decisions about treatment belong with you and your clinician.